Methods of Administering Elagolix

    公开(公告)号:US20250017932A1

    公开(公告)日:2025-01-16

    申请号:US18903555

    申请日:2024-10-01

    Applicant: AbbVie Inc.

    Abstract: The present disclosure relates to the use of GnRH receptor antagonists for the treatment of endometriosis, uterine fibroids, polycystic ovary syndrome (PCOS), or adenomyosis. In particular, the present disclosure describes methods for treating such gynecological disorders, where the methods involve administration of elagolix and may further involve co-administration of a CYP2B6 substrate (e.g., bupropion) or a CYP2C19 substrate (e.g., omeprazole) or a CYP3A4 substrate (e.g., ethinyl estradiol and/or levonorgestrel).

Patent Agency Ranking